LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

Search

Harvard Bioscience Inc

Затворен

СекторЗдравеопазване

0.43 -2.27

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

0.43

Максимум

0.44

Ключови измерители

By Trading Economics

Приходи

48M

-2.3M

Продажби

-1.3M

20M

Марж на печалбата

-11.159

Служители

330

EBITDA

40M

155K

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+288.89% upside

Дивиденти

By Dow Jones

Следващи печалби

6.11.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

2.8M

22M

Предишно отваряне

2.7

Предишно затваряне

0.43

Настроения в новините

By Acuity

50%

50%

173 / 371 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Weak Bearish Evidence

Harvard Bioscience Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

8.09.2025 г., 23:59 ч. UTC

Придобивния, сливания и поглъщания

Anglo American Is in Talks to Buy Teck Resources, Bloomberg Says

8.09.2025 г., 22:02 ч. UTC

Значими двигатели на пазара

Microsoft Signs $17.4 Billion AI Deal With Nebius

8.09.2025 г., 17:01 ч. UTC

Значими двигатели на пазара

Eightco Holdings Stock Surges as Dan Ives Joins Board Amid Crypto Push

8.09.2025 г., 17:01 ч. UTC

Значими двигатели на пазара

Tron Shares Rise After New Investment From Bravemorning

8.09.2025 г., 16:14 ч. UTC

Значими двигатели на пазара

Beyond Air Shares Climb on FDA Orphan Drug Designation for Brain Cancer Treatment

8.09.2025 г., 16:13 ч. UTC

Значими двигатели на пазара

Dianthus Shares Whipsaw on Strong Trial Results, Safety Concerns

8.09.2025 г., 23:12 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

8.09.2025 г., 23:12 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

8.09.2025 г., 23:12 ч. UTC

Пазарно говорене

Infratil's New Bull Likes Exposure to Growing Infrastructure Businesses -- Market Talk

8.09.2025 г., 22:56 ч. UTC

Пазарно говорене

Worst May Be Over for New Zealand Retailers -- Market Talk

8.09.2025 г., 22:23 ч. UTC

Пазарно говорене

Ebos's Near-Term Earnings Outlook Dims -- Market Talk

8.09.2025 г., 21:51 ч. UTC

Пазарно говорене

AT&T Backs Outlook After EchoStar Spectrum Purchase -- Market Talk

8.09.2025 г., 21:47 ч. UTC

Значими двигатели на пазара

Microsoft Signs $17.4B AI Deal With Nebius

8.09.2025 г., 21:33 ч. UTC

Придобивния, сливания и поглъщания

This Quantum Pure Play Is Going Public. What Infleqtion Does Differently, Says Its CEO. -- Barrons.com

8.09.2025 г., 21:20 ч. UTC

Придобивния, сливания и поглъщания

MEG Energy Plans to Respond on or Before Sept 15 >MEG.T

8.09.2025 г., 21:19 ч. UTC

Придобивния, сливания и поглъщания

MEG Energy Special Committee and Board Will Evaluate Revised Strathcona Offer >MEG.T

8.09.2025 г., 21:18 ч. UTC

Придобивния, сливания и поглъщания

MEG Energy Acknowledges Strathcona's Intention to Revise Offer

8.09.2025 г., 20:50 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Tech, Media & Telecom Roundup: Market Talk

8.09.2025 г., 19:33 ч. UTC

Пазарно говорене

Oil Futures Gain Despite Planned OPEC+ Output Increases -- Market Talk

8.09.2025 г., 19:22 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Settle Higher -- Market Talk

8.09.2025 г., 19:02 ч. UTC

Пазарно говорене

Dollar Lukewarm Amid Data Hiatus Ahead of August CPI -- Market Talk

8.09.2025 г., 18:24 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

8.09.2025 г., 18:24 ч. UTC

Пазарно говорене

Weaker Argentine Peso Profitable for Grain Producers -- Market Talk

8.09.2025 г., 17:29 ч. UTC

Пазарно говорене

Mexican Inflation Seen Little Changed in August -- Market Talk

8.09.2025 г., 16:59 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

SpaceX Spectrum Acquisition Will Create More Satellite Connection Supply, Verizon CEO Says -- Market Talk

8.09.2025 г., 16:36 ч. UTC

Пазарно говорене

Crude Futures Hold Gains After OPEC+ Output Decision -- Market Talk

8.09.2025 г., 16:20 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

8.09.2025 г., 16:16 ч. UTC

Печалби

Strategy Stock May Not Ever Make It Into the S&P 500 Index -- Barrons.com

8.09.2025 г., 16:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

8.09.2025 г., 16:04 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

Harvard Bioscience Inc Прогноза

Ценова цел

By TipRanks

288.89% нагоре

12-месечна прогноза

Среден 1.75 USD  288.89%

Висок 3 USD

Нисък 0.5 USD

Според 2 анализатори от Wall Street, предложили 12-месечна ценова цел за Harvard Bioscience Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

2 ratings

1

Купи

1

Задържане

0

Продай

Техническа оценка

By Trading Central

0.3 / 0.3401Подкрепа & съпротива

Краткосрочен план

Weak Bearish Evidence

Средносрочен план

No Evidence

Дългосрочен план

No Evidence

Настроение

By Acuity

173 / 371 Класиране в Здравеопазване

Настроения в новините

Neutral

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Harvard Bioscience Inc

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.
help-icon Live chat